Anlotinib Promising Treatment for Some Sarcomas
by Dr. C.H. Weaver M.D. 6/2019
The tyrosine kinase inhibitor anlotinib delayed time to cancer progression and prolonged survival among patients with soft tissue sarcoma who regressed on or were intolerant to anthracycline-based chemotherapy, according to data presented at the annual American Society of Clinical Oncology Meeting
Chinese doctors assessed 233 Chinese patients with undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, alveolar soft part sarcoma, fibrosarcoma, clear cell sarcoma or epithelioid sarcoma who were treated with anlotinib or a placebo and directly compared.
The overall response rate for anlotinib was 10% and the median time to cancer progression was 6.27 months compared with 1.47 months for placebo treated patients.
ORR was 10.13% among those treated with anlotinib compared with 1.33% for placebo (P < .0145). The disease control rate also was higher with anlotinib (55.7% vs. 22.67%; P < .0001).
In a subgroup analysis, patients with synovial sarcoma leiomyosarcoma, and alveolar soft part sarcoma all had significant improvements, however, among patients with undifferentiated pleomorphic sarcoma, liposarcoma, fibrosarcoma, and clear cell sarcoma the improvements seen with anlotinib were not significant.
Ongoing comparative trials are currently enrolling patients in the United States.
Chi Y, et al. Abstract 11503. Presented at ASCO Annual Meeting; June 1-5, 2018; Chicago.